Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.

Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC.

Am J Psychiatry. 2000 Jun;157(6):975-81.

PMID:
10831479
2.

Clozapine: diabetes mellitus, weight gain, and lipid abnormalities.

Henderson DC.

J Clin Psychiatry. 2001;62 Suppl 23:39-44. Review.

3.

[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].

Wetterling T.

Med Klin (Munich). 2003 Jul 15;98(7):364-7. Review. German.

PMID:
12937901
4.

[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].

Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN.

Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. Review. French.

PMID:
16389718
5.

Consensus development conference on antipsychotic drugs and obesity and diabetes.

American Diabetes Association.; American Psychiatric Association.; American Association of Clinical Endocrinologists.; North American Association for the Study of Obesity..

J Clin Psychiatry. 2004 Feb;65(2):267-72. Review. No abstract available.

PMID:
15003083
6.

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

Stahl SM, Mignon L, Meyer JM.

Acta Psychiatr Scand. 2009 Mar;119(3):171-9. doi: 10.1111/j.1600-0447.2008.01334.x. Review.

PMID:
19178394
7.

Dyslipidemia and atypical antipsychotic drugs.

Casey DE.

J Clin Psychiatry. 2004;65 Suppl 18:27-35. Review.

8.
9.

Hyperglycemia and antipsychotic medications.

Haupt DW, Newcomer JW.

J Clin Psychiatry. 2001;62 Suppl 27:15-26; discussion 40-1. Review.

10.

Consensus development conference on antipsychotic drugs and obesity and diabetes.

American Diabetes Association.; American Psychiatric Association.; American Association of Clinical Endocrinologists.; North American Association for the Study of Obesity..

Obes Res. 2004 Feb;12(2):362-8. Review. No abstract available.

11.

A review of clozapine safety.

Fitzsimons J, Berk M, Lambert T, Bourin M, Dodd S.

Expert Opin Drug Saf. 2005 Jul;4(4):731-44. Review.

PMID:
16011451
12.

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.

McIntyre RS, McCann SM, Kennedy SH.

Can J Psychiatry. 2001 Apr;46(3):273-81. Review.

PMID:
11320682
13.

[Antipsychotic drugs. Risk factors for diabetes].

Stip E, Tranulis C, Légaré N, Poulin MJ.

Presse Med. 2003 Oct 18;32(34):1612-7. Review. French.

PMID:
14576587
14.

Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.

Mayfield K, Siskind D, Winckel K, Russell AW, Kisely S, Smith G, Hollingworth S.

J Psychopharmacol. 2016 Mar;30(3):227-36. doi: 10.1177/0269881115625496. Epub 2016 Jan 22. Review.

PMID:
26801056
15.
16.

[Diabetes as a complication in treatment with second-generation antipsychotics].

Povlsen UJ, Breum L, Lublin HK.

Ugeskr Laeger. 2004 Aug 23;166(35):2977-9. Review. Danish. No abstract available.

PMID:
15387005
17.

Evidence of switching antipsychotic therapy to improve metabolic disturbances.

Wieden PJ, Newcomer JW.

J Clin Psychiatry. 2007 May;68(5):e13. Review. No abstract available.

18.

[Neuroleptic metabolic dysfunctions in patients treated with new generation antipsychotics].

Gorobets LN, Bulanov VS, Vasilenko LM, Litvinov AV, Ivanova GP, Poliakovskaia TP.

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(2):59-68. Review. Russian. No abstract available.

PMID:
24730043
19.

Supplemental Content

Support Center